| Products/Services Used | Details | Operation |
|---|---|---|
| Catalog Antibody | Conjugated antibodies specific for CD4, CD8, CD25, CD137, CD45, CD62L, CD27, CD28 (BD Biosciences), Strep-tag II (Genscript), EGFR (ImClone Systems) and Vβ22 (Beckman Coulter) were used for staining analysis by f low cytometry.... CD45-FITC (BD Pharmagen; Cat: 555482); CD8-PE-Cy7 (BD Pharmagen; Cat: 557746); CD4-APC (BD Pharmagen; Cat: 555349); Strep-tag II Antibody (biotin) (Genscript: Cat: A10737); CD28-PE-Cy7 (BioLegend; Cat: 302925); CD27-PE (eBioscience; Cat: 12-0279); CD62L-APC-Cy7 (BioLegend ; Cat : 304813) ; EGFR ant ibody, ERBITUX (cetux imab) (Bristol-Myers Squibb; NDC: 66733094823); CD25-APC (BD Pharmagen; Cat : 555434) ; StrepTav id in-PE(BD Pharmagen ; Cat : 554061) ; CD28 (BioLegend; Cat: 302902); Propidium Iodine (BD Pharmagen; Cat: 556463). | Get A Quote |
Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells ... More
